Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2939-2947

  Krishna, Rajesh ^a,b,c   McIntosh, Natashia ^a   Riggs, K Wayne ^b   Mayer, Lawrence D ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; MACROGOL DERIVATIVE; PHOSPHATIDYLCHOLINE; VALSPODAR;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED DRUG RELEASE; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EXCRETION; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY CLEARANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BILE; CYCLOSPORINS; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; KIDNEY; LIPOSOMES; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032742140     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Oude Elferink, R. P. J., Meijer, D. K. F., Kuipers, F., Jansen, P. L. M., Groen, A. K., and Groothuis, G. M. M. Hepatobiliary secretion of organic compounds: molecular mechanisms of membrane transport. Biochim. Biophys. Acta, 1241: 215-268, 1995.
2. Meijer, D. K. F., Smit, J. W., and Müller, M. Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters. Adv. Drug Delivery Rev., 25: 159-200, 1997.
3. Steen, H., Oosting, R., and Meijer, D. K. F. Mechanisms for the uptake of cationic drugs by the liver: a study with tributylmethylammonium (TBuMA). J. Pharmacol. Exp. Ther., 258: 537-543, 1991.
4. Martel, F., Vetter, T., Russ, H., Grundemann, D., Azevedo, I., Koepsell, H., and Schomig, E. Transport of small organic cations in the rat liver. The role of the organic cation transporter OCTI. Naunyn-Schmiedeberg's Arch. Pharmacol., 354: 320-326, 1996.
5. Meijer, D. K. F., Mol, W. E. M., Muller, M., Steen, H., and Kurz, G. Carrier-mediated transport in the hepatic distribution and elimination of organic cations. In: K. W. Bock, S. Matern, W. Gerok, and R. Schmid (eds.), Hepatic Metabolism and Disposition of Endo- and Xenobiotics, pp. 259-270. London: Kluwer Academic Publishers, 1991.
6. Sarris, A. H., Younes, A., McLaughlin, P., Moore, D., Hagemeister, F., Swan, F., Rodriguez, M. A., Romaguera, J., North, L., Mansfield, P., Callendar, D., Mesina, O., and Cabanillas, F. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol., 14: 233-239, 1996.
7. Tolcher, A. W., Cowan, K. H., Solomon, D., Ognibene, F., Goldspiel, B., Chang, R., Noone, M. H., Denicoff, A. M., Barnes, C. S., Gossard, M. R., Fetsch, P. A., Berg, S. L., Balis, F. M., Venzon, D. J., and O'Shaughnessy, J. A. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J. Clin. Oncol., 14: 1173-1184, 1996.
8. Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H., and Bleehen, N. M. Phase I study of etoposide with PSC-833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol., 14: 610-618, 1996.
9. Schinkel, A. H., Smit, J. J. M., Van Tellingen, O., Beijnen, J. H., Wagenaar, E., Van Deemter, L., Mol, C. A. A. M., Van Der Valk, M. A., Robanus-Maandag, E. C., Te Riele, H. P. J., Berns, A. J. M., and Borst, P. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensitivity to drugs. Cell. 77: N491-N502, 1994.
10. Schinkel, A. H., Wagenaar, E., Van Deemter, L., Mol, C. A. A. M., and Borst, P. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Investig., 96: 1698-1705, 1995.
11. Sparreboom, A., Van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., and Van Tellingen, O. Limited oral bio-availability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA, 94: 2031-2035, 1997.
12. Stapf, V., Thalhammer, T., Huber-Huber, R., Felberbauer, F., Gajdzik, L., and Graf, J. Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver. Anticancer Res., 14: 581-585, 1994.
13. Watanabe, T., Miyauchi, S., Sawada, Y., Iga, T., Hanano, M., Inaba, M., and Sugiyama, Y. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. J. Hepatol., 16: 77-88, 1992.
14. Speeg, K. V., Maldonado, A. L., Liaci, J., and Muirhead, D. Effect of cyclosporin on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology, 15: 899-903, 1992.
15. Speeg, K. V., and Maldonado, A. L. Effect of the non-immunosuppressive cyclosporine analogue SDZ PSC 833 on colchicine and doxorubicin biliary secretion in the rat in vivo. Cancer Chemother. Pharmacol., 34: 133-136, 1994.
16. Booth, C. L., Brouwer, K. R., and Brouwer, K. L. R. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res., 58: 3641-3648, 1998.
17. Smit, J. W., Duin, E., Steen, H., Oosting, R., Roggeveld, J., and Meijer, D. K. F. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br. J. Pharmacol., 123: 361-370, 1998.
18. Cusack, B. J., Young, S. P., Driskell, J., and Olson, R. D. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother. Pharmacol., 32: 53-58, 1993.
19. Riggs, C. E., Benjamin, R. S., Serpick, A. A., and Bachur, N. R. Biliary disposition of Adriamycin. Clin. Pharmacol. Ther., 22: 234-241, 1977.
20. Yesair, D. W., Schwartzbach, E., Shuck, D., Denine, E. P., and Asbell, M. A. Comparative pharmacokinetics of daunomycin and Adriamycin in several animal species. Cancer Res., 32: 1177-1183, 1972.
21. Tavoloni, N., and Guarino, A. Biliary and urinary excretion of Adriamycin in anesthetized rats. Phamacology, 20: 256-267, 1980.
22. Speeg, K., Malonado, A., Liaci, J., and Muirhead, D. Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo. J. Pharmacol. Exp. Ther., 261: 50-55, 1992.
23. Krishna, R., and Mayer, L. D. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug resistant solid tumors. Cancer Res., 57: 5246-5253, 1997.
24. Krishna, R., St. Louis, M., and Mayer L. D. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug resistant solid tumors by co-administering Valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int. J. Cancer, in press, 1999.
25. Mayer, L. D., Hope, M. J., and Cullis, P. R. Vesicles of various sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta, 858: 161-168, 1986.
26. Derksen, J. T. P., Morselt, H. W. M., and Scherphof, G. L. Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim. Biophys. Acta, 931: 33-40, 1987.
27. Mayer, L. D., Bally, M. B., and Cullis, P. R. Uptake of Adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta, 857: 123-126, 1986.
28. Keller, R. P., Altermatt, H. J., Nooter, K., Poschmann, G., Laissue, J. A., Bollinger, P., and Hiestand, P. C. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50: 593-597, 1992.
29. Andersen, A., Warren, D. J., and Stordal, L. A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther. Drug Monit., 15: 455-461, 1993.
30. Parker, R. J., Priester, E. R., and Sieber, S. M. Effect of route administration and liposome entrapment on the metabolism and disposition of Adriamycin in the rat. Drug Metab. Dispos., 10: 499-504, 1982.
31. Gabizon, A. A., Barenholz, Y., and Bialer, M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res. (NY), 10: 703-708, 1993.
32. Spanjer, H. H., van Galen, M., Roerdink, F. H., Regts, J., and Scherphof, G. L. Intrahepatic distribution of small unilamellar liposomes as a function of liposomal lipid composition. Biochim. Biophys. Acta, 863: 224-230, 1986.
33. Mayer, L. D., Tai, L. C. L., Ko, D. S. C., Masin, D., Ginsberg, R. S., Cullis, P. R., and Bally, M. B. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res., 49: 5922-5930, 1989.
34. Scherphof, G. L., Roerdink, F., Dijkstra, J., Ellens, H., De Zanger, R., and Wisse, E. Uptake of liposomes by rat and mouse hepatocytes and Kupffer cells. Biol. Cell, 47: 47-58, 1983.
35. Sperker, B., Murdter, T. E., Schick, M., Eckhardt, K., Bosslet, K., and Kroemer, H. K. Interindividual variability in expression and activity of human β-glucuronidase in liver and kidney: consequences for drug metabolism. J. Pharmacol. Exp. Ther., 281: 914-920, 1997.
36. Colombo, T., Donelli, M. G., Urso, R., Dallarda, S., Bartosek, J., and Guaitani, A. Doxorubicin toxicity and pharmacokinetics in old and young rats. Exp. Gerontol., 24: 159-171, 1989.